Live Feeds
● LIVE Updated 1h ago · 7 sources tracked

Why the latest heart drug failures should make us all more skeptical of AI hype

Novartis' pelacarsen trial showed zero benefit for lowering Lp(a) cholesterol, stunning cardiologists who had high hopes for the inherited heart-risk treatment. Simultaneously, a promising cholesterol drug from Novo Nordisk failed to prevent heart attacks or strokes in a major trial. These back-to-back flops have left experts guessing about the biological pathways targeted and cast a shadow over similar programs at Amgen and Eli Lilly. The STAT analysis argues these failures should temper enthusiasm for AI hype in drug development, as computational predictions did not translate into clinical success.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis' pelacarsen trial demonstrated zero clinical benefit for patients with elevated Lp(a) levels.
  • ✓ A Novo Nordisk heart drug failed to prevent heart attacks or strokes in a major clinical trial.
  • ✓ The pelacarsen failure casts doubt on the viability of similar Lp(a)-targeting programs at Amgen and Eli Lilly.
  • ✓ Experts are surprised by the trial outcomes, which contradicted strong genetic and epidemiological evidence.
🛡️ Source Corroboration: 7 independent reporting domains (88% confidence) ⏱ Read time: ~2 min

What changed

Novartis' pelacarsen Phase 3 trial failed to show benefit, and a Novo Nordisk cardiovascular outcome trial also missed its primary endpoint, triggering industry-wide reassessment.

Live updates

  1. Heart drug failures fuel skepticism about AI-driven drug discovery

    Novartis' pelacarsen trial showed zero benefit for lowering Lp(a) cholesterol, stunning cardiologists who had high hopes for the inherited heart-risk treatment. Simultaneously, a promising cholesterol drug from Novo Nordisk failed to prevent heart attacks or strokes in a major trial. These back-to-back flops have left experts guessing about the biological pathways targeted and cast a shadow over similar programs at Amgen and Eli Lilly. The STAT analysis argues these failures should temper enthusiasm for AI hype in drug development, as computational predictions did not translate into clinical success.

    Why it matters

    Cardiologists had viewed pelacarsen and the Novo Nordisk candidate as potential breakthroughs for residual cardiovascular risk not addressed by statins. The Lp(a) pathway in particular was considered a 'slam dunk' target due to strong genetic evidence linking high levels to heart disease. The failures suggest that lowering a biomarker does not guarantee clinical benefit, a lesson with broad implications for drug development strategy and the role of AI in target selection.

    What is confirmed

    • Novartis' pelacarsen trial demonstrated zero clinical benefit for patients with elevated Lp(a) levels.
    • A Novo Nordisk heart drug failed to prevent heart attacks or strokes in a major clinical trial.
    • The pelacarsen failure casts doubt on the viability of similar Lp(a)-targeting programs at Amgen and Eli Lilly.
    • Experts are surprised by the trial outcomes, which contradicted strong genetic and epidemiological evidence.

    Still unconfirmed

    • AI-driven target identification may have overpromised on the translatability of biomarker modulation to clinical outcomes.

    What to watch next

    • Amgen and Eli Lilly Lp(a) program readouts
    • Regulatory feedback on biomarker-based approval pathways
    • Analysis of why Lp(a) lowering did not reduce cardiovascular events
    Sources used for this update (7)
    1. NPR — A promising new medicine against heart disease fails unexpectedly
    2. CNN — Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
    3. The New York Times — How Cardiologists’ High Hopes for Two Drugs Were Dashed
    4. NBC News — The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
    5. Fierce Biotech — Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
    6. Reuters — Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
    7. STAT — Why the latest heart drug failures should make us all more skeptical of AI hype
    confidence 88%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community